Oral semaglutide provides superior HbA1c and weight

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
68
Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial

Bagsværd, Denmark, 20 August 2018 - Novo Nordisk today announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults with type 2 diabetes and moderate renal impairment. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 26-week trial investigated the efficacy and safety of 14 mg oral semaglutide compared with placebo in 324 people with type 2 diabetes and moderate renal impairment inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.

Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 5 trial; a primary statistical approach [1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach [2] describing the effect while on treatment and without use of rescue medication.

The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA 1c with oral semaglutide compared to placebo at week 26. Furthermore, people treated with oral semaglutide achieved statistically significant and superior reductions in body weight compared to placebo at week 26.

When applying the secondary statistical approach, people treated with oral semaglutide experienced a statistically significantly greater reduction in HbA 1c of 1.1% compared to 0.1% with placebo. Reduction in body weight was statistically significantly greater with oral semaglutide at week 26, with a reduction of 3.7 kg compared to 1.1 kg with placebo. From a baseline HbA 1c of 8.0%, the proportion of people achieving the American Diabetes Association (ADA) target of HbA 1c below 7.0% was statistically significantly greater with 14 mg oral semaglutide, with 64% achieving the target at week 26, compared to 21% with placebo.

In this 26-week trial, oral semaglutide was well-tolerated in people with moderate renal impairment, with a profile consistent with GLP-1-based therapies. The most common adverse event for oral semaglutide was mild to moderate nausea. In PIONEER 5, 19% of people treated with oral semaglutide experienced nausea, compared to 8% of people treated with placebo. The proportion of people who discontinued treatment due to adverse events was 15% for people treated with oral semaglutide compared to 6% with placebo.

"The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people."

About PIONEER 5 and the PIONEER clinical trial programme

PIONEER 5 was a 26-week, randomised, double-blind, placebo-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of 14 mg oral semaglutide with placebo in people with type 2 diabetes and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 ml/min/1.73m 2 ) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin. PIONEER 5 randomised 324 people in a 1:1 manner to receive either a dose of 14 mg oral semaglutide or placebo once daily. The primary endpoint was change from baseline to week 26 in HbA 1c . Key secondary endpoints included change in body weight, change in fasting plasma glucose from baseline to week 26 and proportion of people achieving HbA 1c below 7.0% at 26 weeks.

The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Twitter , LinkedIn , YouTube .

Further information

Media:    
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors :    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com

                

 Company announcement No 66 / 2018

[1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)).

[2] Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 34

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 55

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 183

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 67

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 147

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 0

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading

Top 5 Most Recently Viewed Articles

Wesdome Gold Mines Pursues Significant Share Repurchase Plan

Updated Category News Views 220

Wesdome Gold Mines Initiates Share Buyback Program Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) is excited to unveil its plan for a Normal Course Issuer Bid (NCIB), which has just received approval from its board of directors and is pending final consent from the Toronto Stock Exchange (TSX). This strategic initiative allows the company to buy back a substantial 2% of...

Continue Reading
Zillow Faces August Class Action Deadline: Investor Alert

Updated Category News Views 51

Investor Tensions Rise Ahead of Zillow's Legal Deadline August 10, 2026—mark it down. That's your last call to jump into the fray with the class action suit against Zillow Group, Inc. (NASDAQ: ZG, Z), should you have skin in the game. We're talking investors who bought into Zillow from February 11, 2025, through May 7, 2026. Yeah, 'investor alert' might as well be...

Continue Reading
Explore Opportunities in the 2025 Global Omics Sciences Contest

Updated Category News Views 214

Unveiling the 2025 Mammoth International Contest on Omics Sciences Guided by esteemed organizations like UNESCO, the 2025 Mammoth International Contest on Omics Sciences offers young scientists an incredible platform to showcase their talents and innovative ideas. This initiative is proudly co-organized by BGI Research and the Jinze Charitable Foundation, unveiling a new...

Continue Reading
Navigating Disagreements: Jeff Bezos' Unique Leadership Style

Updated Category News Views 544

Embracing Different Perspectives: Jeff Bezos' Approach In a recent discussion, Jeff Bezos, the founder of Amazon.com, Inc. (NASDAQ: AMZN), reflected on his distinctive methodology for making decisions quickly and effectively. He believes that fostering an environment of trust and open dialogue is essential for overcoming disagreements. The Philosophy of Disagree and...

Continue Reading
Exploring Philanthropy's Impact on the U.S.-Mexico Border

Updated Category News Views 273

Unveiling Border Briefs in San Diego Recently, the U.S.-Mexico Border Philanthropy Partnership (BPP) introduced the Border Briefs series during an impactful event named Voices and Visions from the Border: A Funder Dialogue. This gathering was held at the San Diego Central Library, aiming to highlight the dynamic role that philanthropy plays in addressing challenges and...

Continue Reading